J MOL MED 润色咨询

JOURNAL OF MOLECULAR MEDICINE-JMM

出版年份:1995 年文章数:1975 投稿命中率: 开通期刊会员,数据随心看

出版周期:Monthly 自引率:2.0% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2110629, encodeId=6a23211062944, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向:蛋白翻译后修饰;单基因遗传病<br>经验分享:22-08-17投稿,22-12-17一审审完,给了major revision,本来是22-12-26修修回的,但是J Mol Med杂志系统出问题,不能提交修回稿件,23-01-02才提交成功,23-01-17顺利接收。虽然前后花了5个月,但是总的来说,编辑部很负责人,你问的问题都能及时回答,也有耐心。J Mol Med是经典的老牌杂志,审稿严格,性价比都挺高,而且可以不交版面费。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c482066161, createdName=周郎, createdTime=Tue Jan 17 21:37:05 CST 2023, time=2023-01-17, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2174957, encodeId=66d421e4957ce, content=偏重的研究方向:肿瘤<br>经验分享:审了7个月给我拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db776430639, createdName=ms4000000529451557, createdTime=Thu Dec 14 17:16:05 CST 2023, time=2023-12-14, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2130655, encodeId=7b3b2130655f8, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:免疫;肿瘤;分子机制<br>经验分享:22.11.02投稿<br>22.11.03with editor<br>22.11.16under review<br>然后一直没邀请到审稿人,直到23.02.25审稿人同意审稿<br>23.03.10审稿结束with editor<br>23.03.18major revision<br>23.04.26大修返稿 with editor<br>23.04.27under review审稿人同意二审<br>23.05.01with editor<br>23.05.02二审需要修改细节 编辑说修改后接收 当天二审返修<br>23.05.04Accept<br>我的是7500-8000字左右的非邀请综述,两张图一个表格,感觉编辑和审稿人非常友好,大修问题不多,效率高。主要前期四个月一直没邀请到审稿人,但是我没催稿就一直等,审稿人同意审稿后,返修接收就很快了,只能说好事多磨,个人觉得投稿难度不大,希望能帮助到大家。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3ae8324464, createdName=ms7000001464324828, createdTime=Sun May 07 00:57:48 CST 2023, time=2023-05-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=574694, encodeId=b7b05e469453, content=请问后面是多少天有变化的呢?谢谢<span class="quote">放开和放 2018-07-25 发表::<br>七月初投的,为何现在还是with editor,正常吗?不是杂志处理挺快的吗?</span><span class="quote">放开和放 2018-07-25 08:54:00 发表:<br>七月初投的,为何现在还是with editor,正常吗?不是杂志处理挺快的吗?</span>, beContent=放开和放 2018-07-25 发表:: 七月初投的,为何现在还是with editor,正常吗?不是杂志处理挺快的吗?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200728/1059765ccd8a40aa986926e2fe3bbf96/a8f6a6380fca49ff8f429655d566033f.jpg, createdBy=71f05115585, createdName=14624ce9m23暂无昵称, createdTime=Mon Aug 12 00:00:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2153586, encodeId=b6972153586bd, content=请问该杂志接收基础研究关于结肠癌的文章投稿吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4bf8174298, createdName=ms2000001056499310, createdTime=Sat Aug 19 13:48:05 CST 2023, time=2023-08-19, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2152911, encodeId=f2c92152911db, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:罕见遗传代谢病<br>经验分享:先经过一轮大修,再小修后接收。老牌期刊,审稿严格,相比其他发文量大的二区水刊这个期刊值得投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbac6398987, createdName=ms4000001377912728, createdTime=Tue Aug 15 17:36:45 CST 2023, time=2023-08-15, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=565347, encodeId=252556534eee, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:非约稿综述,写了7000-8000字,2个表,2个图,参考文献150个,美国bioedit语言润色后投稿。 <br> 9月初投, <br> 11月初一审意见返回 20几条修改意见 小修 <br> 12月初加了一个表格,机制图全部重画。修后再投 <br> 12月中旬二审意见,其他评委通过,还有一个评委建议小修 <br> 12月底修后再投 <br> 1月8日通知收稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a77a1532040, createdName=15531030, createdTime=Wed Jan 09 01:14:00 CST 2019, time=2019-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2122066, encodeId=98f9212206662, content=投稿快3个月了,还是在 Under Review中,期间写信问过一次,杂志回信说还未收到第二个审稿人的意见,这又过去一个月了,还没有进展,杂志也没有让我新推荐审稿人。这能不能写信建议杂志换审稿人啦?感觉太拖沓了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67d41839407, createdName=ms3552943899811193, createdTime=Mon Mar 27 14:45:50 CST 2023, time=2023-03-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=587219, encodeId=a5f158e21939, content=3.9投稿,3.13with editor,3.17收到邮件要求提供Western原图,然后就一直是with editor了。在杂志主页上看到平均时间26天有结果,不知道怎么还没有送出外审呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6a1643864, createdName=monica77, createdTime=Mon Mar 23 14:47:00 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093710, encodeId=18e91093e10f8, content=水刊真的不值得选择吗?什么情况下可选择水刊投稿?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=)]
    2023-01-17 周郎 来自贵州省

    审稿速度:6.0 | 投稿命中率:25.0
    偏重的研究方向:蛋白翻译后修饰;单基因遗传病
    经验分享:22-08-17投稿,22-12-17一审审完,给了major revision,本来是22-12-26修修回的,但是J Mol Med杂志系统出问题,不能提交修回稿件,23-01-02才提交成功,23-01-17顺利接收。虽然前后花了5个月,但是总的来说,编辑部很负责人,你问的问题都能及时回答,也有耐心。J Mol Med是经典的老牌杂志,审稿严格,性价比都挺高,而且可以不交版面费。

    5

    展开5条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2110629, encodeId=6a23211062944, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向:蛋白翻译后修饰;单基因遗传病<br>经验分享:22-08-17投稿,22-12-17一审审完,给了major revision,本来是22-12-26修修回的,但是J Mol Med杂志系统出问题,不能提交修回稿件,23-01-02才提交成功,23-01-17顺利接收。虽然前后花了5个月,但是总的来说,编辑部很负责人,你问的问题都能及时回答,也有耐心。J Mol Med是经典的老牌杂志,审稿严格,性价比都挺高,而且可以不交版面费。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c482066161, createdName=周郎, createdTime=Tue Jan 17 21:37:05 CST 2023, time=2023-01-17, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2174957, encodeId=66d421e4957ce, content=偏重的研究方向:肿瘤<br>经验分享:审了7个月给我拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db776430639, createdName=ms4000000529451557, createdTime=Thu Dec 14 17:16:05 CST 2023, time=2023-12-14, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2130655, encodeId=7b3b2130655f8, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:免疫;肿瘤;分子机制<br>经验分享:22.11.02投稿<br>22.11.03with editor<br>22.11.16under review<br>然后一直没邀请到审稿人,直到23.02.25审稿人同意审稿<br>23.03.10审稿结束with editor<br>23.03.18major revision<br>23.04.26大修返稿 with editor<br>23.04.27under review审稿人同意二审<br>23.05.01with editor<br>23.05.02二审需要修改细节 编辑说修改后接收 当天二审返修<br>23.05.04Accept<br>我的是7500-8000字左右的非邀请综述,两张图一个表格,感觉编辑和审稿人非常友好,大修问题不多,效率高。主要前期四个月一直没邀请到审稿人,但是我没催稿就一直等,审稿人同意审稿后,返修接收就很快了,只能说好事多磨,个人觉得投稿难度不大,希望能帮助到大家。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3ae8324464, createdName=ms7000001464324828, createdTime=Sun May 07 00:57:48 CST 2023, time=2023-05-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=574694, encodeId=b7b05e469453, content=请问后面是多少天有变化的呢?谢谢<span class="quote">放开和放 2018-07-25 发表::<br>七月初投的,为何现在还是with editor,正常吗?不是杂志处理挺快的吗?</span><span class="quote">放开和放 2018-07-25 08:54:00 发表:<br>七月初投的,为何现在还是with editor,正常吗?不是杂志处理挺快的吗?</span>, beContent=放开和放 2018-07-25 发表:: 七月初投的,为何现在还是with editor,正常吗?不是杂志处理挺快的吗?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200728/1059765ccd8a40aa986926e2fe3bbf96/a8f6a6380fca49ff8f429655d566033f.jpg, createdBy=71f05115585, createdName=14624ce9m23暂无昵称, createdTime=Mon Aug 12 00:00:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2153586, encodeId=b6972153586bd, content=请问该杂志接收基础研究关于结肠癌的文章投稿吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4bf8174298, createdName=ms2000001056499310, createdTime=Sat Aug 19 13:48:05 CST 2023, time=2023-08-19, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2152911, encodeId=f2c92152911db, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:罕见遗传代谢病<br>经验分享:先经过一轮大修,再小修后接收。老牌期刊,审稿严格,相比其他发文量大的二区水刊这个期刊值得投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbac6398987, createdName=ms4000001377912728, createdTime=Tue Aug 15 17:36:45 CST 2023, time=2023-08-15, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=565347, encodeId=252556534eee, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:非约稿综述,写了7000-8000字,2个表,2个图,参考文献150个,美国bioedit语言润色后投稿。 <br> 9月初投, <br> 11月初一审意见返回 20几条修改意见 小修 <br> 12月初加了一个表格,机制图全部重画。修后再投 <br> 12月中旬二审意见,其他评委通过,还有一个评委建议小修 <br> 12月底修后再投 <br> 1月8日通知收稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a77a1532040, createdName=15531030, createdTime=Wed Jan 09 01:14:00 CST 2019, time=2019-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2122066, encodeId=98f9212206662, content=投稿快3个月了,还是在 Under Review中,期间写信问过一次,杂志回信说还未收到第二个审稿人的意见,这又过去一个月了,还没有进展,杂志也没有让我新推荐审稿人。这能不能写信建议杂志换审稿人啦?感觉太拖沓了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67d41839407, createdName=ms3552943899811193, createdTime=Mon Mar 27 14:45:50 CST 2023, time=2023-03-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=587219, encodeId=a5f158e21939, content=3.9投稿,3.13with editor,3.17收到邮件要求提供Western原图,然后就一直是with editor了。在杂志主页上看到平均时间26天有结果,不知道怎么还没有送出外审呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6a1643864, createdName=monica77, createdTime=Mon Mar 23 14:47:00 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093710, encodeId=18e91093e10f8, content=水刊真的不值得选择吗?什么情况下可选择水刊投稿?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=)]
    2023-12-14 ms4000000529451557 来自河南省

    偏重的研究方向:肿瘤
    经验分享:审了7个月给我拒了

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2110629, encodeId=6a23211062944, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向:蛋白翻译后修饰;单基因遗传病<br>经验分享:22-08-17投稿,22-12-17一审审完,给了major revision,本来是22-12-26修修回的,但是J Mol Med杂志系统出问题,不能提交修回稿件,23-01-02才提交成功,23-01-17顺利接收。虽然前后花了5个月,但是总的来说,编辑部很负责人,你问的问题都能及时回答,也有耐心。J Mol Med是经典的老牌杂志,审稿严格,性价比都挺高,而且可以不交版面费。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c482066161, createdName=周郎, createdTime=Tue Jan 17 21:37:05 CST 2023, time=2023-01-17, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2174957, encodeId=66d421e4957ce, content=偏重的研究方向:肿瘤<br>经验分享:审了7个月给我拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db776430639, createdName=ms4000000529451557, createdTime=Thu Dec 14 17:16:05 CST 2023, time=2023-12-14, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2130655, encodeId=7b3b2130655f8, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:免疫;肿瘤;分子机制<br>经验分享:22.11.02投稿<br>22.11.03with editor<br>22.11.16under review<br>然后一直没邀请到审稿人,直到23.02.25审稿人同意审稿<br>23.03.10审稿结束with editor<br>23.03.18major revision<br>23.04.26大修返稿 with editor<br>23.04.27under review审稿人同意二审<br>23.05.01with editor<br>23.05.02二审需要修改细节 编辑说修改后接收 当天二审返修<br>23.05.04Accept<br>我的是7500-8000字左右的非邀请综述,两张图一个表格,感觉编辑和审稿人非常友好,大修问题不多,效率高。主要前期四个月一直没邀请到审稿人,但是我没催稿就一直等,审稿人同意审稿后,返修接收就很快了,只能说好事多磨,个人觉得投稿难度不大,希望能帮助到大家。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3ae8324464, createdName=ms7000001464324828, createdTime=Sun May 07 00:57:48 CST 2023, time=2023-05-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=574694, encodeId=b7b05e469453, content=请问后面是多少天有变化的呢?谢谢<span class="quote">放开和放 2018-07-25 发表::<br>七月初投的,为何现在还是with editor,正常吗?不是杂志处理挺快的吗?</span><span class="quote">放开和放 2018-07-25 08:54:00 发表:<br>七月初投的,为何现在还是with editor,正常吗?不是杂志处理挺快的吗?</span>, beContent=放开和放 2018-07-25 发表:: 七月初投的,为何现在还是with editor,正常吗?不是杂志处理挺快的吗?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200728/1059765ccd8a40aa986926e2fe3bbf96/a8f6a6380fca49ff8f429655d566033f.jpg, createdBy=71f05115585, createdName=14624ce9m23暂无昵称, createdTime=Mon Aug 12 00:00:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2153586, encodeId=b6972153586bd, content=请问该杂志接收基础研究关于结肠癌的文章投稿吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4bf8174298, createdName=ms2000001056499310, createdTime=Sat Aug 19 13:48:05 CST 2023, time=2023-08-19, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2152911, encodeId=f2c92152911db, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:罕见遗传代谢病<br>经验分享:先经过一轮大修,再小修后接收。老牌期刊,审稿严格,相比其他发文量大的二区水刊这个期刊值得投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbac6398987, createdName=ms4000001377912728, createdTime=Tue Aug 15 17:36:45 CST 2023, time=2023-08-15, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=565347, encodeId=252556534eee, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:非约稿综述,写了7000-8000字,2个表,2个图,参考文献150个,美国bioedit语言润色后投稿。 <br> 9月初投, <br> 11月初一审意见返回 20几条修改意见 小修 <br> 12月初加了一个表格,机制图全部重画。修后再投 <br> 12月中旬二审意见,其他评委通过,还有一个评委建议小修 <br> 12月底修后再投 <br> 1月8日通知收稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a77a1532040, createdName=15531030, createdTime=Wed Jan 09 01:14:00 CST 2019, time=2019-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2122066, encodeId=98f9212206662, content=投稿快3个月了,还是在 Under Review中,期间写信问过一次,杂志回信说还未收到第二个审稿人的意见,这又过去一个月了,还没有进展,杂志也没有让我新推荐审稿人。这能不能写信建议杂志换审稿人啦?感觉太拖沓了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67d41839407, createdName=ms3552943899811193, createdTime=Mon Mar 27 14:45:50 CST 2023, time=2023-03-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=587219, encodeId=a5f158e21939, content=3.9投稿,3.13with editor,3.17收到邮件要求提供Western原图,然后就一直是with editor了。在杂志主页上看到平均时间26天有结果,不知道怎么还没有送出外审呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6a1643864, createdName=monica77, createdTime=Mon Mar 23 14:47:00 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093710, encodeId=18e91093e10f8, content=水刊真的不值得选择吗?什么情况下可选择水刊投稿?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=)]
    2023-05-07 ms7000001464324828 来自湖南省

    审稿速度:6.0 | 投稿命中率:75.0
    偏重的研究方向:免疫;肿瘤;分子机制
    经验分享:22.11.02投稿
    22.11.03with editor
    22.11.16under review
    然后一直没邀请到审稿人,直到23.02.25审稿人同意审稿
    23.03.10审稿结束with editor
    23.03.18major revision
    23.04.26大修返稿 with editor
    23.04.27under review审稿人同意二审
    23.05.01with editor
    23.05.02二审需要修改细节 编辑说修改后接收 当天二审返修
    23.05.04Accept
    我的是7500-8000字左右的非邀请综述,两张图一个表格,感觉编辑和审稿人非常友好,大修问题不多,效率高。主要前期四个月一直没邀请到审稿人,但是我没催稿就一直等,审稿人同意审稿后,返修接收就很快了,只能说好事多磨,个人觉得投稿难度不大,希望能帮助到大家。

    3

    展开3条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2110629, encodeId=6a23211062944, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向:蛋白翻译后修饰;单基因遗传病<br>经验分享:22-08-17投稿,22-12-17一审审完,给了major revision,本来是22-12-26修修回的,但是J Mol Med杂志系统出问题,不能提交修回稿件,23-01-02才提交成功,23-01-17顺利接收。虽然前后花了5个月,但是总的来说,编辑部很负责人,你问的问题都能及时回答,也有耐心。J Mol Med是经典的老牌杂志,审稿严格,性价比都挺高,而且可以不交版面费。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c482066161, createdName=周郎, createdTime=Tue Jan 17 21:37:05 CST 2023, time=2023-01-17, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2174957, encodeId=66d421e4957ce, content=偏重的研究方向:肿瘤<br>经验分享:审了7个月给我拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db776430639, createdName=ms4000000529451557, createdTime=Thu Dec 14 17:16:05 CST 2023, time=2023-12-14, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2130655, encodeId=7b3b2130655f8, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:免疫;肿瘤;分子机制<br>经验分享:22.11.02投稿<br>22.11.03with editor<br>22.11.16under review<br>然后一直没邀请到审稿人,直到23.02.25审稿人同意审稿<br>23.03.10审稿结束with editor<br>23.03.18major revision<br>23.04.26大修返稿 with editor<br>23.04.27under review审稿人同意二审<br>23.05.01with editor<br>23.05.02二审需要修改细节 编辑说修改后接收 当天二审返修<br>23.05.04Accept<br>我的是7500-8000字左右的非邀请综述,两张图一个表格,感觉编辑和审稿人非常友好,大修问题不多,效率高。主要前期四个月一直没邀请到审稿人,但是我没催稿就一直等,审稿人同意审稿后,返修接收就很快了,只能说好事多磨,个人觉得投稿难度不大,希望能帮助到大家。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3ae8324464, createdName=ms7000001464324828, createdTime=Sun May 07 00:57:48 CST 2023, time=2023-05-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=574694, encodeId=b7b05e469453, content=请问后面是多少天有变化的呢?谢谢<span class="quote">放开和放 2018-07-25 发表::<br>七月初投的,为何现在还是with editor,正常吗?不是杂志处理挺快的吗?</span><span class="quote">放开和放 2018-07-25 08:54:00 发表:<br>七月初投的,为何现在还是with editor,正常吗?不是杂志处理挺快的吗?</span>, beContent=放开和放 2018-07-25 发表:: 七月初投的,为何现在还是with editor,正常吗?不是杂志处理挺快的吗?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200728/1059765ccd8a40aa986926e2fe3bbf96/a8f6a6380fca49ff8f429655d566033f.jpg, createdBy=71f05115585, createdName=14624ce9m23暂无昵称, createdTime=Mon Aug 12 00:00:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2153586, encodeId=b6972153586bd, content=请问该杂志接收基础研究关于结肠癌的文章投稿吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4bf8174298, createdName=ms2000001056499310, createdTime=Sat Aug 19 13:48:05 CST 2023, time=2023-08-19, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2152911, encodeId=f2c92152911db, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:罕见遗传代谢病<br>经验分享:先经过一轮大修,再小修后接收。老牌期刊,审稿严格,相比其他发文量大的二区水刊这个期刊值得投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbac6398987, createdName=ms4000001377912728, createdTime=Tue Aug 15 17:36:45 CST 2023, time=2023-08-15, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=565347, encodeId=252556534eee, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:非约稿综述,写了7000-8000字,2个表,2个图,参考文献150个,美国bioedit语言润色后投稿。 <br> 9月初投, <br> 11月初一审意见返回 20几条修改意见 小修 <br> 12月初加了一个表格,机制图全部重画。修后再投 <br> 12月中旬二审意见,其他评委通过,还有一个评委建议小修 <br> 12月底修后再投 <br> 1月8日通知收稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a77a1532040, createdName=15531030, createdTime=Wed Jan 09 01:14:00 CST 2019, time=2019-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2122066, encodeId=98f9212206662, content=投稿快3个月了,还是在 Under Review中,期间写信问过一次,杂志回信说还未收到第二个审稿人的意见,这又过去一个月了,还没有进展,杂志也没有让我新推荐审稿人。这能不能写信建议杂志换审稿人啦?感觉太拖沓了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67d41839407, createdName=ms3552943899811193, createdTime=Mon Mar 27 14:45:50 CST 2023, time=2023-03-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=587219, encodeId=a5f158e21939, content=3.9投稿,3.13with editor,3.17收到邮件要求提供Western原图,然后就一直是with editor了。在杂志主页上看到平均时间26天有结果,不知道怎么还没有送出外审呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6a1643864, createdName=monica77, createdTime=Mon Mar 23 14:47:00 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093710, encodeId=18e91093e10f8, content=水刊真的不值得选择吗?什么情况下可选择水刊投稿?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=)]
    2019-08-12 14624ce9m23暂无昵称

    请问后面是多少天有变化的呢?谢谢放开和放 2018-07-25 发表::
    七月初投的,为何现在还是with editor,正常吗?不是杂志处理挺快的吗?
    放开和放 2018-07-25 08:54:00 发表:
    七月初投的,为何现在还是with editor,正常吗?不是杂志处理挺快的吗?

    放开和放 2018-07-25 发表:: 七月初投的,为何现在还是with editor,正常吗?不是杂志处理挺快的吗?

    1

    展开1条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2110629, encodeId=6a23211062944, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向:蛋白翻译后修饰;单基因遗传病<br>经验分享:22-08-17投稿,22-12-17一审审完,给了major revision,本来是22-12-26修修回的,但是J Mol Med杂志系统出问题,不能提交修回稿件,23-01-02才提交成功,23-01-17顺利接收。虽然前后花了5个月,但是总的来说,编辑部很负责人,你问的问题都能及时回答,也有耐心。J Mol Med是经典的老牌杂志,审稿严格,性价比都挺高,而且可以不交版面费。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c482066161, createdName=周郎, createdTime=Tue Jan 17 21:37:05 CST 2023, time=2023-01-17, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2174957, encodeId=66d421e4957ce, content=偏重的研究方向:肿瘤<br>经验分享:审了7个月给我拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db776430639, createdName=ms4000000529451557, createdTime=Thu Dec 14 17:16:05 CST 2023, time=2023-12-14, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2130655, encodeId=7b3b2130655f8, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:免疫;肿瘤;分子机制<br>经验分享:22.11.02投稿<br>22.11.03with editor<br>22.11.16under review<br>然后一直没邀请到审稿人,直到23.02.25审稿人同意审稿<br>23.03.10审稿结束with editor<br>23.03.18major revision<br>23.04.26大修返稿 with editor<br>23.04.27under review审稿人同意二审<br>23.05.01with editor<br>23.05.02二审需要修改细节 编辑说修改后接收 当天二审返修<br>23.05.04Accept<br>我的是7500-8000字左右的非邀请综述,两张图一个表格,感觉编辑和审稿人非常友好,大修问题不多,效率高。主要前期四个月一直没邀请到审稿人,但是我没催稿就一直等,审稿人同意审稿后,返修接收就很快了,只能说好事多磨,个人觉得投稿难度不大,希望能帮助到大家。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3ae8324464, createdName=ms7000001464324828, createdTime=Sun May 07 00:57:48 CST 2023, time=2023-05-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=574694, encodeId=b7b05e469453, content=请问后面是多少天有变化的呢?谢谢<span class="quote">放开和放 2018-07-25 发表::<br>七月初投的,为何现在还是with editor,正常吗?不是杂志处理挺快的吗?</span><span class="quote">放开和放 2018-07-25 08:54:00 发表:<br>七月初投的,为何现在还是with editor,正常吗?不是杂志处理挺快的吗?</span>, beContent=放开和放 2018-07-25 发表:: 七月初投的,为何现在还是with editor,正常吗?不是杂志处理挺快的吗?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200728/1059765ccd8a40aa986926e2fe3bbf96/a8f6a6380fca49ff8f429655d566033f.jpg, createdBy=71f05115585, createdName=14624ce9m23暂无昵称, createdTime=Mon Aug 12 00:00:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2153586, encodeId=b6972153586bd, content=请问该杂志接收基础研究关于结肠癌的文章投稿吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4bf8174298, createdName=ms2000001056499310, createdTime=Sat Aug 19 13:48:05 CST 2023, time=2023-08-19, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2152911, encodeId=f2c92152911db, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:罕见遗传代谢病<br>经验分享:先经过一轮大修,再小修后接收。老牌期刊,审稿严格,相比其他发文量大的二区水刊这个期刊值得投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbac6398987, createdName=ms4000001377912728, createdTime=Tue Aug 15 17:36:45 CST 2023, time=2023-08-15, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=565347, encodeId=252556534eee, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:非约稿综述,写了7000-8000字,2个表,2个图,参考文献150个,美国bioedit语言润色后投稿。 <br> 9月初投, <br> 11月初一审意见返回 20几条修改意见 小修 <br> 12月初加了一个表格,机制图全部重画。修后再投 <br> 12月中旬二审意见,其他评委通过,还有一个评委建议小修 <br> 12月底修后再投 <br> 1月8日通知收稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a77a1532040, createdName=15531030, createdTime=Wed Jan 09 01:14:00 CST 2019, time=2019-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2122066, encodeId=98f9212206662, content=投稿快3个月了,还是在 Under Review中,期间写信问过一次,杂志回信说还未收到第二个审稿人的意见,这又过去一个月了,还没有进展,杂志也没有让我新推荐审稿人。这能不能写信建议杂志换审稿人啦?感觉太拖沓了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67d41839407, createdName=ms3552943899811193, createdTime=Mon Mar 27 14:45:50 CST 2023, time=2023-03-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=587219, encodeId=a5f158e21939, content=3.9投稿,3.13with editor,3.17收到邮件要求提供Western原图,然后就一直是with editor了。在杂志主页上看到平均时间26天有结果,不知道怎么还没有送出外审呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6a1643864, createdName=monica77, createdTime=Mon Mar 23 14:47:00 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093710, encodeId=18e91093e10f8, content=水刊真的不值得选择吗?什么情况下可选择水刊投稿?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=)]
    2023-08-19 ms2000001056499310 来自山东省

    请问该杂志接收基础研究关于结肠癌的文章投稿吗?

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2110629, encodeId=6a23211062944, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向:蛋白翻译后修饰;单基因遗传病<br>经验分享:22-08-17投稿,22-12-17一审审完,给了major revision,本来是22-12-26修修回的,但是J Mol Med杂志系统出问题,不能提交修回稿件,23-01-02才提交成功,23-01-17顺利接收。虽然前后花了5个月,但是总的来说,编辑部很负责人,你问的问题都能及时回答,也有耐心。J Mol Med是经典的老牌杂志,审稿严格,性价比都挺高,而且可以不交版面费。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c482066161, createdName=周郎, createdTime=Tue Jan 17 21:37:05 CST 2023, time=2023-01-17, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2174957, encodeId=66d421e4957ce, content=偏重的研究方向:肿瘤<br>经验分享:审了7个月给我拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db776430639, createdName=ms4000000529451557, createdTime=Thu Dec 14 17:16:05 CST 2023, time=2023-12-14, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2130655, encodeId=7b3b2130655f8, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:免疫;肿瘤;分子机制<br>经验分享:22.11.02投稿<br>22.11.03with editor<br>22.11.16under review<br>然后一直没邀请到审稿人,直到23.02.25审稿人同意审稿<br>23.03.10审稿结束with editor<br>23.03.18major revision<br>23.04.26大修返稿 with editor<br>23.04.27under review审稿人同意二审<br>23.05.01with editor<br>23.05.02二审需要修改细节 编辑说修改后接收 当天二审返修<br>23.05.04Accept<br>我的是7500-8000字左右的非邀请综述,两张图一个表格,感觉编辑和审稿人非常友好,大修问题不多,效率高。主要前期四个月一直没邀请到审稿人,但是我没催稿就一直等,审稿人同意审稿后,返修接收就很快了,只能说好事多磨,个人觉得投稿难度不大,希望能帮助到大家。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3ae8324464, createdName=ms7000001464324828, createdTime=Sun May 07 00:57:48 CST 2023, time=2023-05-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=574694, encodeId=b7b05e469453, content=请问后面是多少天有变化的呢?谢谢<span class="quote">放开和放 2018-07-25 发表::<br>七月初投的,为何现在还是with editor,正常吗?不是杂志处理挺快的吗?</span><span class="quote">放开和放 2018-07-25 08:54:00 发表:<br>七月初投的,为何现在还是with editor,正常吗?不是杂志处理挺快的吗?</span>, beContent=放开和放 2018-07-25 发表:: 七月初投的,为何现在还是with editor,正常吗?不是杂志处理挺快的吗?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200728/1059765ccd8a40aa986926e2fe3bbf96/a8f6a6380fca49ff8f429655d566033f.jpg, createdBy=71f05115585, createdName=14624ce9m23暂无昵称, createdTime=Mon Aug 12 00:00:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2153586, encodeId=b6972153586bd, content=请问该杂志接收基础研究关于结肠癌的文章投稿吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4bf8174298, createdName=ms2000001056499310, createdTime=Sat Aug 19 13:48:05 CST 2023, time=2023-08-19, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2152911, encodeId=f2c92152911db, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:罕见遗传代谢病<br>经验分享:先经过一轮大修,再小修后接收。老牌期刊,审稿严格,相比其他发文量大的二区水刊这个期刊值得投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbac6398987, createdName=ms4000001377912728, createdTime=Tue Aug 15 17:36:45 CST 2023, time=2023-08-15, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=565347, encodeId=252556534eee, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:非约稿综述,写了7000-8000字,2个表,2个图,参考文献150个,美国bioedit语言润色后投稿。 <br> 9月初投, <br> 11月初一审意见返回 20几条修改意见 小修 <br> 12月初加了一个表格,机制图全部重画。修后再投 <br> 12月中旬二审意见,其他评委通过,还有一个评委建议小修 <br> 12月底修后再投 <br> 1月8日通知收稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a77a1532040, createdName=15531030, createdTime=Wed Jan 09 01:14:00 CST 2019, time=2019-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2122066, encodeId=98f9212206662, content=投稿快3个月了,还是在 Under Review中,期间写信问过一次,杂志回信说还未收到第二个审稿人的意见,这又过去一个月了,还没有进展,杂志也没有让我新推荐审稿人。这能不能写信建议杂志换审稿人啦?感觉太拖沓了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67d41839407, createdName=ms3552943899811193, createdTime=Mon Mar 27 14:45:50 CST 2023, time=2023-03-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=587219, encodeId=a5f158e21939, content=3.9投稿,3.13with editor,3.17收到邮件要求提供Western原图,然后就一直是with editor了。在杂志主页上看到平均时间26天有结果,不知道怎么还没有送出外审呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6a1643864, createdName=monica77, createdTime=Mon Mar 23 14:47:00 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093710, encodeId=18e91093e10f8, content=水刊真的不值得选择吗?什么情况下可选择水刊投稿?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=)]
    2023-08-15 ms4000001377912728 来自山东省

    审稿速度:3.0 | 投稿命中率:50.0
    偏重的研究方向:罕见遗传代谢病
    经验分享:先经过一轮大修,再小修后接收。老牌期刊,审稿严格,相比其他发文量大的二区水刊这个期刊值得投稿。

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2110629, encodeId=6a23211062944, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向:蛋白翻译后修饰;单基因遗传病<br>经验分享:22-08-17投稿,22-12-17一审审完,给了major revision,本来是22-12-26修修回的,但是J Mol Med杂志系统出问题,不能提交修回稿件,23-01-02才提交成功,23-01-17顺利接收。虽然前后花了5个月,但是总的来说,编辑部很负责人,你问的问题都能及时回答,也有耐心。J Mol Med是经典的老牌杂志,审稿严格,性价比都挺高,而且可以不交版面费。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c482066161, createdName=周郎, createdTime=Tue Jan 17 21:37:05 CST 2023, time=2023-01-17, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2174957, encodeId=66d421e4957ce, content=偏重的研究方向:肿瘤<br>经验分享:审了7个月给我拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db776430639, createdName=ms4000000529451557, createdTime=Thu Dec 14 17:16:05 CST 2023, time=2023-12-14, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2130655, encodeId=7b3b2130655f8, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:免疫;肿瘤;分子机制<br>经验分享:22.11.02投稿<br>22.11.03with editor<br>22.11.16under review<br>然后一直没邀请到审稿人,直到23.02.25审稿人同意审稿<br>23.03.10审稿结束with editor<br>23.03.18major revision<br>23.04.26大修返稿 with editor<br>23.04.27under review审稿人同意二审<br>23.05.01with editor<br>23.05.02二审需要修改细节 编辑说修改后接收 当天二审返修<br>23.05.04Accept<br>我的是7500-8000字左右的非邀请综述,两张图一个表格,感觉编辑和审稿人非常友好,大修问题不多,效率高。主要前期四个月一直没邀请到审稿人,但是我没催稿就一直等,审稿人同意审稿后,返修接收就很快了,只能说好事多磨,个人觉得投稿难度不大,希望能帮助到大家。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3ae8324464, createdName=ms7000001464324828, createdTime=Sun May 07 00:57:48 CST 2023, time=2023-05-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=574694, encodeId=b7b05e469453, content=请问后面是多少天有变化的呢?谢谢<span class="quote">放开和放 2018-07-25 发表::<br>七月初投的,为何现在还是with editor,正常吗?不是杂志处理挺快的吗?</span><span class="quote">放开和放 2018-07-25 08:54:00 发表:<br>七月初投的,为何现在还是with editor,正常吗?不是杂志处理挺快的吗?</span>, beContent=放开和放 2018-07-25 发表:: 七月初投的,为何现在还是with editor,正常吗?不是杂志处理挺快的吗?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200728/1059765ccd8a40aa986926e2fe3bbf96/a8f6a6380fca49ff8f429655d566033f.jpg, createdBy=71f05115585, createdName=14624ce9m23暂无昵称, createdTime=Mon Aug 12 00:00:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2153586, encodeId=b6972153586bd, content=请问该杂志接收基础研究关于结肠癌的文章投稿吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4bf8174298, createdName=ms2000001056499310, createdTime=Sat Aug 19 13:48:05 CST 2023, time=2023-08-19, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2152911, encodeId=f2c92152911db, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:罕见遗传代谢病<br>经验分享:先经过一轮大修,再小修后接收。老牌期刊,审稿严格,相比其他发文量大的二区水刊这个期刊值得投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbac6398987, createdName=ms4000001377912728, createdTime=Tue Aug 15 17:36:45 CST 2023, time=2023-08-15, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=565347, encodeId=252556534eee, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:非约稿综述,写了7000-8000字,2个表,2个图,参考文献150个,美国bioedit语言润色后投稿。 <br> 9月初投, <br> 11月初一审意见返回 20几条修改意见 小修 <br> 12月初加了一个表格,机制图全部重画。修后再投 <br> 12月中旬二审意见,其他评委通过,还有一个评委建议小修 <br> 12月底修后再投 <br> 1月8日通知收稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a77a1532040, createdName=15531030, createdTime=Wed Jan 09 01:14:00 CST 2019, time=2019-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2122066, encodeId=98f9212206662, content=投稿快3个月了,还是在 Under Review中,期间写信问过一次,杂志回信说还未收到第二个审稿人的意见,这又过去一个月了,还没有进展,杂志也没有让我新推荐审稿人。这能不能写信建议杂志换审稿人啦?感觉太拖沓了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67d41839407, createdName=ms3552943899811193, createdTime=Mon Mar 27 14:45:50 CST 2023, time=2023-03-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=587219, encodeId=a5f158e21939, content=3.9投稿,3.13with editor,3.17收到邮件要求提供Western原图,然后就一直是with editor了。在杂志主页上看到平均时间26天有结果,不知道怎么还没有送出外审呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6a1643864, createdName=monica77, createdTime=Mon Mar 23 14:47:00 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093710, encodeId=18e91093e10f8, content=水刊真的不值得选择吗?什么情况下可选择水刊投稿?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=)]
    2019-01-09 15531030

    审稿速度:2.0 | 投稿命中率:25.0
    经验分享:非约稿综述,写了7000-8000字,2个表,2个图,参考文献150个,美国bioedit语言润色后投稿。
    9月初投,
    11月初一审意见返回 20几条修改意见 小修
    12月初加了一个表格,机制图全部重画。修后再投
    12月中旬二审意见,其他评委通过,还有一个评委建议小修
    12月底修后再投
    1月8日通知收稿。

    3

    展开3条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2110629, encodeId=6a23211062944, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向:蛋白翻译后修饰;单基因遗传病<br>经验分享:22-08-17投稿,22-12-17一审审完,给了major revision,本来是22-12-26修修回的,但是J Mol Med杂志系统出问题,不能提交修回稿件,23-01-02才提交成功,23-01-17顺利接收。虽然前后花了5个月,但是总的来说,编辑部很负责人,你问的问题都能及时回答,也有耐心。J Mol Med是经典的老牌杂志,审稿严格,性价比都挺高,而且可以不交版面费。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c482066161, createdName=周郎, createdTime=Tue Jan 17 21:37:05 CST 2023, time=2023-01-17, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2174957, encodeId=66d421e4957ce, content=偏重的研究方向:肿瘤<br>经验分享:审了7个月给我拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db776430639, createdName=ms4000000529451557, createdTime=Thu Dec 14 17:16:05 CST 2023, time=2023-12-14, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2130655, encodeId=7b3b2130655f8, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:免疫;肿瘤;分子机制<br>经验分享:22.11.02投稿<br>22.11.03with editor<br>22.11.16under review<br>然后一直没邀请到审稿人,直到23.02.25审稿人同意审稿<br>23.03.10审稿结束with editor<br>23.03.18major revision<br>23.04.26大修返稿 with editor<br>23.04.27under review审稿人同意二审<br>23.05.01with editor<br>23.05.02二审需要修改细节 编辑说修改后接收 当天二审返修<br>23.05.04Accept<br>我的是7500-8000字左右的非邀请综述,两张图一个表格,感觉编辑和审稿人非常友好,大修问题不多,效率高。主要前期四个月一直没邀请到审稿人,但是我没催稿就一直等,审稿人同意审稿后,返修接收就很快了,只能说好事多磨,个人觉得投稿难度不大,希望能帮助到大家。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3ae8324464, createdName=ms7000001464324828, createdTime=Sun May 07 00:57:48 CST 2023, time=2023-05-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=574694, encodeId=b7b05e469453, content=请问后面是多少天有变化的呢?谢谢<span class="quote">放开和放 2018-07-25 发表::<br>七月初投的,为何现在还是with editor,正常吗?不是杂志处理挺快的吗?</span><span class="quote">放开和放 2018-07-25 08:54:00 发表:<br>七月初投的,为何现在还是with editor,正常吗?不是杂志处理挺快的吗?</span>, beContent=放开和放 2018-07-25 发表:: 七月初投的,为何现在还是with editor,正常吗?不是杂志处理挺快的吗?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200728/1059765ccd8a40aa986926e2fe3bbf96/a8f6a6380fca49ff8f429655d566033f.jpg, createdBy=71f05115585, createdName=14624ce9m23暂无昵称, createdTime=Mon Aug 12 00:00:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2153586, encodeId=b6972153586bd, content=请问该杂志接收基础研究关于结肠癌的文章投稿吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4bf8174298, createdName=ms2000001056499310, createdTime=Sat Aug 19 13:48:05 CST 2023, time=2023-08-19, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2152911, encodeId=f2c92152911db, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:罕见遗传代谢病<br>经验分享:先经过一轮大修,再小修后接收。老牌期刊,审稿严格,相比其他发文量大的二区水刊这个期刊值得投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbac6398987, createdName=ms4000001377912728, createdTime=Tue Aug 15 17:36:45 CST 2023, time=2023-08-15, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=565347, encodeId=252556534eee, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:非约稿综述,写了7000-8000字,2个表,2个图,参考文献150个,美国bioedit语言润色后投稿。 <br> 9月初投, <br> 11月初一审意见返回 20几条修改意见 小修 <br> 12月初加了一个表格,机制图全部重画。修后再投 <br> 12月中旬二审意见,其他评委通过,还有一个评委建议小修 <br> 12月底修后再投 <br> 1月8日通知收稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a77a1532040, createdName=15531030, createdTime=Wed Jan 09 01:14:00 CST 2019, time=2019-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2122066, encodeId=98f9212206662, content=投稿快3个月了,还是在 Under Review中,期间写信问过一次,杂志回信说还未收到第二个审稿人的意见,这又过去一个月了,还没有进展,杂志也没有让我新推荐审稿人。这能不能写信建议杂志换审稿人啦?感觉太拖沓了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67d41839407, createdName=ms3552943899811193, createdTime=Mon Mar 27 14:45:50 CST 2023, time=2023-03-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=587219, encodeId=a5f158e21939, content=3.9投稿,3.13with editor,3.17收到邮件要求提供Western原图,然后就一直是with editor了。在杂志主页上看到平均时间26天有结果,不知道怎么还没有送出外审呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6a1643864, createdName=monica77, createdTime=Mon Mar 23 14:47:00 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093710, encodeId=18e91093e10f8, content=水刊真的不值得选择吗?什么情况下可选择水刊投稿?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=)]
    2023-03-27 ms3552943899811193 来自重庆

    投稿快3个月了,还是在 Under Review中,期间写信问过一次,杂志回信说还未收到第二个审稿人的意见,这又过去一个月了,还没有进展,杂志也没有让我新推荐审稿人。这能不能写信建议杂志换审稿人啦?感觉太拖沓了。

    9

    展开9条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2110629, encodeId=6a23211062944, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向:蛋白翻译后修饰;单基因遗传病<br>经验分享:22-08-17投稿,22-12-17一审审完,给了major revision,本来是22-12-26修修回的,但是J Mol Med杂志系统出问题,不能提交修回稿件,23-01-02才提交成功,23-01-17顺利接收。虽然前后花了5个月,但是总的来说,编辑部很负责人,你问的问题都能及时回答,也有耐心。J Mol Med是经典的老牌杂志,审稿严格,性价比都挺高,而且可以不交版面费。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c482066161, createdName=周郎, createdTime=Tue Jan 17 21:37:05 CST 2023, time=2023-01-17, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2174957, encodeId=66d421e4957ce, content=偏重的研究方向:肿瘤<br>经验分享:审了7个月给我拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db776430639, createdName=ms4000000529451557, createdTime=Thu Dec 14 17:16:05 CST 2023, time=2023-12-14, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2130655, encodeId=7b3b2130655f8, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:免疫;肿瘤;分子机制<br>经验分享:22.11.02投稿<br>22.11.03with editor<br>22.11.16under review<br>然后一直没邀请到审稿人,直到23.02.25审稿人同意审稿<br>23.03.10审稿结束with editor<br>23.03.18major revision<br>23.04.26大修返稿 with editor<br>23.04.27under review审稿人同意二审<br>23.05.01with editor<br>23.05.02二审需要修改细节 编辑说修改后接收 当天二审返修<br>23.05.04Accept<br>我的是7500-8000字左右的非邀请综述,两张图一个表格,感觉编辑和审稿人非常友好,大修问题不多,效率高。主要前期四个月一直没邀请到审稿人,但是我没催稿就一直等,审稿人同意审稿后,返修接收就很快了,只能说好事多磨,个人觉得投稿难度不大,希望能帮助到大家。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3ae8324464, createdName=ms7000001464324828, createdTime=Sun May 07 00:57:48 CST 2023, time=2023-05-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=574694, encodeId=b7b05e469453, content=请问后面是多少天有变化的呢?谢谢<span class="quote">放开和放 2018-07-25 发表::<br>七月初投的,为何现在还是with editor,正常吗?不是杂志处理挺快的吗?</span><span class="quote">放开和放 2018-07-25 08:54:00 发表:<br>七月初投的,为何现在还是with editor,正常吗?不是杂志处理挺快的吗?</span>, beContent=放开和放 2018-07-25 发表:: 七月初投的,为何现在还是with editor,正常吗?不是杂志处理挺快的吗?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200728/1059765ccd8a40aa986926e2fe3bbf96/a8f6a6380fca49ff8f429655d566033f.jpg, createdBy=71f05115585, createdName=14624ce9m23暂无昵称, createdTime=Mon Aug 12 00:00:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2153586, encodeId=b6972153586bd, content=请问该杂志接收基础研究关于结肠癌的文章投稿吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4bf8174298, createdName=ms2000001056499310, createdTime=Sat Aug 19 13:48:05 CST 2023, time=2023-08-19, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2152911, encodeId=f2c92152911db, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:罕见遗传代谢病<br>经验分享:先经过一轮大修,再小修后接收。老牌期刊,审稿严格,相比其他发文量大的二区水刊这个期刊值得投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbac6398987, createdName=ms4000001377912728, createdTime=Tue Aug 15 17:36:45 CST 2023, time=2023-08-15, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=565347, encodeId=252556534eee, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:非约稿综述,写了7000-8000字,2个表,2个图,参考文献150个,美国bioedit语言润色后投稿。 <br> 9月初投, <br> 11月初一审意见返回 20几条修改意见 小修 <br> 12月初加了一个表格,机制图全部重画。修后再投 <br> 12月中旬二审意见,其他评委通过,还有一个评委建议小修 <br> 12月底修后再投 <br> 1月8日通知收稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a77a1532040, createdName=15531030, createdTime=Wed Jan 09 01:14:00 CST 2019, time=2019-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2122066, encodeId=98f9212206662, content=投稿快3个月了,还是在 Under Review中,期间写信问过一次,杂志回信说还未收到第二个审稿人的意见,这又过去一个月了,还没有进展,杂志也没有让我新推荐审稿人。这能不能写信建议杂志换审稿人啦?感觉太拖沓了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67d41839407, createdName=ms3552943899811193, createdTime=Mon Mar 27 14:45:50 CST 2023, time=2023-03-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=587219, encodeId=a5f158e21939, content=3.9投稿,3.13with editor,3.17收到邮件要求提供Western原图,然后就一直是with editor了。在杂志主页上看到平均时间26天有结果,不知道怎么还没有送出外审呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6a1643864, createdName=monica77, createdTime=Mon Mar 23 14:47:00 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093710, encodeId=18e91093e10f8, content=水刊真的不值得选择吗?什么情况下可选择水刊投稿?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=)]
    2020-03-23 monica77

    3.9投稿,3.13with editor,3.17收到邮件要求提供Western原图,然后就一直是with editor了。在杂志主页上看到平均时间26天有结果,不知道怎么还没有送出外审呢?

    5

    展开5条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2110629, encodeId=6a23211062944, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向:蛋白翻译后修饰;单基因遗传病<br>经验分享:22-08-17投稿,22-12-17一审审完,给了major revision,本来是22-12-26修修回的,但是J Mol Med杂志系统出问题,不能提交修回稿件,23-01-02才提交成功,23-01-17顺利接收。虽然前后花了5个月,但是总的来说,编辑部很负责人,你问的问题都能及时回答,也有耐心。J Mol Med是经典的老牌杂志,审稿严格,性价比都挺高,而且可以不交版面费。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c482066161, createdName=周郎, createdTime=Tue Jan 17 21:37:05 CST 2023, time=2023-01-17, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2174957, encodeId=66d421e4957ce, content=偏重的研究方向:肿瘤<br>经验分享:审了7个月给我拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db776430639, createdName=ms4000000529451557, createdTime=Thu Dec 14 17:16:05 CST 2023, time=2023-12-14, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2130655, encodeId=7b3b2130655f8, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:免疫;肿瘤;分子机制<br>经验分享:22.11.02投稿<br>22.11.03with editor<br>22.11.16under review<br>然后一直没邀请到审稿人,直到23.02.25审稿人同意审稿<br>23.03.10审稿结束with editor<br>23.03.18major revision<br>23.04.26大修返稿 with editor<br>23.04.27under review审稿人同意二审<br>23.05.01with editor<br>23.05.02二审需要修改细节 编辑说修改后接收 当天二审返修<br>23.05.04Accept<br>我的是7500-8000字左右的非邀请综述,两张图一个表格,感觉编辑和审稿人非常友好,大修问题不多,效率高。主要前期四个月一直没邀请到审稿人,但是我没催稿就一直等,审稿人同意审稿后,返修接收就很快了,只能说好事多磨,个人觉得投稿难度不大,希望能帮助到大家。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3ae8324464, createdName=ms7000001464324828, createdTime=Sun May 07 00:57:48 CST 2023, time=2023-05-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=574694, encodeId=b7b05e469453, content=请问后面是多少天有变化的呢?谢谢<span class="quote">放开和放 2018-07-25 发表::<br>七月初投的,为何现在还是with editor,正常吗?不是杂志处理挺快的吗?</span><span class="quote">放开和放 2018-07-25 08:54:00 发表:<br>七月初投的,为何现在还是with editor,正常吗?不是杂志处理挺快的吗?</span>, beContent=放开和放 2018-07-25 发表:: 七月初投的,为何现在还是with editor,正常吗?不是杂志处理挺快的吗?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200728/1059765ccd8a40aa986926e2fe3bbf96/a8f6a6380fca49ff8f429655d566033f.jpg, createdBy=71f05115585, createdName=14624ce9m23暂无昵称, createdTime=Mon Aug 12 00:00:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2153586, encodeId=b6972153586bd, content=请问该杂志接收基础研究关于结肠癌的文章投稿吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4bf8174298, createdName=ms2000001056499310, createdTime=Sat Aug 19 13:48:05 CST 2023, time=2023-08-19, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2152911, encodeId=f2c92152911db, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:罕见遗传代谢病<br>经验分享:先经过一轮大修,再小修后接收。老牌期刊,审稿严格,相比其他发文量大的二区水刊这个期刊值得投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbac6398987, createdName=ms4000001377912728, createdTime=Tue Aug 15 17:36:45 CST 2023, time=2023-08-15, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=565347, encodeId=252556534eee, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:非约稿综述,写了7000-8000字,2个表,2个图,参考文献150个,美国bioedit语言润色后投稿。 <br> 9月初投, <br> 11月初一审意见返回 20几条修改意见 小修 <br> 12月初加了一个表格,机制图全部重画。修后再投 <br> 12月中旬二审意见,其他评委通过,还有一个评委建议小修 <br> 12月底修后再投 <br> 1月8日通知收稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a77a1532040, createdName=15531030, createdTime=Wed Jan 09 01:14:00 CST 2019, time=2019-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2122066, encodeId=98f9212206662, content=投稿快3个月了,还是在 Under Review中,期间写信问过一次,杂志回信说还未收到第二个审稿人的意见,这又过去一个月了,还没有进展,杂志也没有让我新推荐审稿人。这能不能写信建议杂志换审稿人啦?感觉太拖沓了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67d41839407, createdName=ms3552943899811193, createdTime=Mon Mar 27 14:45:50 CST 2023, time=2023-03-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=587219, encodeId=a5f158e21939, content=3.9投稿,3.13with editor,3.17收到邮件要求提供Western原图,然后就一直是with editor了。在杂志主页上看到平均时间26天有结果,不知道怎么还没有送出外审呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6a1643864, createdName=monica77, createdTime=Mon Mar 23 14:47:00 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093710, encodeId=18e91093e10f8, content=水刊真的不值得选择吗?什么情况下可选择水刊投稿?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=)]
    2021-12-27 学医的彭于晏

    水刊真的不值得选择吗?什么情况下可选择水刊投稿?

    1

    展开1条回复
共79条页码: 1/8页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分